The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes
Mosquitoes are vectors of major diseases such as dengue fever and malaria. Mass drug administration of endectocides to humans and livestock is a promising complementary approach to current insecticide-based vector control measures. The aim of this study was to establish an insect model for pharmacok...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2021
|
| _version_ | 1826263163908128768 |
|---|---|
| author | Duthaler, U Weber, M Hofer, L Chaccour, C Maia, M Müller, P Krähenbühl, S Hammann, F |
| author_facet | Duthaler, U Weber, M Hofer, L Chaccour, C Maia, M Müller, P Krähenbühl, S Hammann, F |
| author_sort | Duthaler, U |
| collection | OXFORD |
| description | Mosquitoes are vectors of major diseases such as dengue fever and malaria. Mass drug administration of endectocides to humans and livestock is a promising complementary approach to current insecticide-based vector control measures. The aim of this study was to establish an insect model for pharmacokinetic and drug-drug interaction studies to develop sustainable endectocides for vector control. Female Aedes aegypti mosquitoes were fed with human blood containing either ivermectin alone or ivermectin in combination with ketoconazole, rifampicin, ritonavir, or piperonyl butoxide. Drug concentrations were quantified by LC-MS/MS at selected time points post-feeding. Primary pharmacokinetic parameters and extent of drug-drug interactions were calculated by pharmacometric modelling. Lastly, the drug effect of the treatments was examined. The mosquitoes could be dosed with a high precision (%CV: ≤13.4%) over a range of 0.01–1 μg/ml ivermectin without showing saturation (R2: 0.99). The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0–19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1–5.9 pg/h). By contrast, ketoconazole, ritonavir, and piperonyl butoxide were immediately excreted following first order elimination, whereas rifampicin accumulated over days in the mosquitoes. Ritonavir increased the lag phase of ivermectin by 11.4 h (CI90%: 8.7–14.2 h) resulting in an increased exposure (+29%) and an enhanced mosquitocidal effect. In summary, this study shows that the pharmacokinetics of drugs can be investigated and modulated in an Ae. aegypti animal model. This may help in the development of novel vector-control interventions and further our understanding of toxicology in arthropods. |
| first_indexed | 2024-03-06T19:47:21Z |
| format | Journal article |
| id | oxford-uuid:22c46eaa-fa81-441c-9733-3e4a3f5e2c08 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:47:21Z |
| publishDate | 2021 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:22c46eaa-fa81-441c-9733-3e4a3f5e2c082022-03-26T11:40:35ZThe pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:22c46eaa-fa81-441c-9733-3e4a3f5e2c08EnglishSymplectic ElementsPublic Library of Science2021Duthaler, UWeber, MHofer, LChaccour, CMaia, MMüller, PKrähenbühl, SHammann, FMosquitoes are vectors of major diseases such as dengue fever and malaria. Mass drug administration of endectocides to humans and livestock is a promising complementary approach to current insecticide-based vector control measures. The aim of this study was to establish an insect model for pharmacokinetic and drug-drug interaction studies to develop sustainable endectocides for vector control. Female Aedes aegypti mosquitoes were fed with human blood containing either ivermectin alone or ivermectin in combination with ketoconazole, rifampicin, ritonavir, or piperonyl butoxide. Drug concentrations were quantified by LC-MS/MS at selected time points post-feeding. Primary pharmacokinetic parameters and extent of drug-drug interactions were calculated by pharmacometric modelling. Lastly, the drug effect of the treatments was examined. The mosquitoes could be dosed with a high precision (%CV: ≤13.4%) over a range of 0.01–1 μg/ml ivermectin without showing saturation (R2: 0.99). The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0–19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1–5.9 pg/h). By contrast, ketoconazole, ritonavir, and piperonyl butoxide were immediately excreted following first order elimination, whereas rifampicin accumulated over days in the mosquitoes. Ritonavir increased the lag phase of ivermectin by 11.4 h (CI90%: 8.7–14.2 h) resulting in an increased exposure (+29%) and an enhanced mosquitocidal effect. In summary, this study shows that the pharmacokinetics of drugs can be investigated and modulated in an Ae. aegypti animal model. This may help in the development of novel vector-control interventions and further our understanding of toxicology in arthropods. |
| spellingShingle | Duthaler, U Weber, M Hofer, L Chaccour, C Maia, M Müller, P Krähenbühl, S Hammann, F The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title | The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title_full | The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title_fullStr | The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title_full_unstemmed | The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title_short | The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes |
| title_sort | pharmacokinetics and drug drug interactions of ivermectin in aedes aegypti mosquitoes |
| work_keys_str_mv | AT duthaleru thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT weberm thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT hoferl thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT chaccourc thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT maiam thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT mullerp thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT krahenbuhls thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT hammannf thepharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT duthaleru pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT weberm pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT hoferl pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT chaccourc pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT maiam pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT mullerp pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT krahenbuhls pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes AT hammannf pharmacokineticsanddrugdruginteractionsofivermectininaedesaegyptimosquitoes |